News

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other indications, today announced the acceptance of an abstract for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31 – June 4, 2024.

04/29/2024

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.

04/24/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Pasithea Therapeutics Corp. (KTTA) a buy, sell, or hold?

Pasithea Therapeutics Corp. (KTTA) can sell. Click on Rating Page for detail.

What is Pasithea Therapeutics Corp.'s stock price?

The price of Pasithea Therapeutics Corp. (KTTA) is 6.6 and it was updated on 2024-05-18 07:01:14.

Is Pasithea Therapeutics Corp. (KTTA) overvalued or undervalued?

Currently Pasithea Therapeutics Corp. (KTTA) is in undervalued.

News

From:

To:

News
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 -- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europe in the coming months -- -- Preliminary interim data expected in 2H 2024 -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the activation of four clinical trial sites in the United States. Tue, Feb. 13, 2024
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position -- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced the invention of a crystalline form of PAS-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045. Mon, Jan. 08, 2024
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients -- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as early as Q3 2024 – SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced the Investigational New Drug Application (IND) clearance to proceed by the U.S. Federal Drug Administration (FDA) to evaluate PAS-004, a macrocyclic MEK (1/2) inhibitor, in patients with MAPK pathway driven advanced solid tumors with a documented RAS, RAF or NF1 mutation or patients who have failed BRAF/MEK inhibition. Tue, Jan. 02, 2024
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19. Thu, Dec. 28, 2023
Pasithea Therapeutics Announces Results from 2023 Annual Meeting SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 19, 2023. Tue, Dec. 19, 2023

SEC Filings

SEC Filings
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 05/14/2024
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 05/14/2024
Pasithea Therapeutics Corp. (KTTA) - 4/A SEC Filings 04/05/2024
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 04/03/2024
Pasithea Therapeutics Corp. (KTTA) - S-8 SEC Filings 03/29/2024
Pasithea Therapeutics Corp. (KTTA) - POS AM SEC Filings 03/29/2024
Pasithea Therapeutics Corp. (KTTA) - 10-K - Current report SEC Filings 03/29/2024
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 03/01/2024
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 01/18/2024
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 01/02/2024
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 12/28/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 12/28/2023
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 12/19/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 12/19/2023
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 11/29/2023
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 11/13/2023
Pasithea Therapeutics Corp. (KTTA) - DEF 14A SEC Filings 10/26/2023
Pasithea Therapeutics Corp. (KTTA) - ARS SEC Filings 10/26/2023
Pasithea Therapeutics Corp. (KTTA) - PRE 14A SEC Filings 10/16/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 10/13/2023
Pasithea Therapeutics Corp. (KTTA) - SC TO-I/A SEC Filings 09/14/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 09/14/2023
Pasithea Therapeutics Corp. (KTTA) - SC TO-I/A SEC Filings 08/24/2023
Pasithea Therapeutics Corp. (KTTA) - SC TO-I/A SEC Filings 08/21/2023
Pasithea Therapeutics Corp. (KTTA) - SC TO-I/A SEC Filings 08/14/2023
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 08/11/2023
Pasithea Therapeutics Corp. (KTTA) - SC TO-I SEC Filings 08/09/2023
Pasithea Therapeutics Corp. (KTTA) - SC TO-C SEC Filings 07/20/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 07/20/2023
Pasithea Therapeutics Corp. (KTTA) - 3 SEC Filings 07/03/2023
Pasithea Therapeutics Corp. (KTTA) - SC 13D SEC Filings 06/08/2023
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 06/06/2023
Pasithea Therapeutics Corp. (KTTA) - 424B3 SEC Filings 06/06/2023
Pasithea Therapeutics Corp. (KTTA) - 4/A SEC Filings 06/06/2023
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 06/06/2023
Pasithea Therapeutics Corp. (KTTA) - DEL AM SEC Filings 05/17/2023
Pasithea Therapeutics Corp. (KTTA) - S-3 SEC Filings 05/12/2023
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 05/12/2023
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 04/20/2023
Pasithea Therapeutics Corp. (KTTA) - 10-K/A - Current report SEC Filings 04/04/2023
Pasithea Therapeutics Corp. (KTTA) - S-8 SEC Filings 03/30/2023
Pasithea Therapeutics Corp. (KTTA) - S-3 SEC Filings 03/30/2023
Pasithea Therapeutics Corp. (KTTA) - 10-K - Current report SEC Filings 03/30/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 03/10/2023
Pasithea Therapeutics Corp. (KTTA) - SC 13G/A SEC Filings 02/15/2023
Pasithea Therapeutics Corp. (KTTA) - 3 SEC Filings 02/14/2023
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 01/24/2023
Pasithea Therapeutics Corp. (KTTA) - SC 13G/A SEC Filings 01/13/2023
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 01/10/2023
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 12/14/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 12/14/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 12/07/2022
Pasithea Therapeutics Corp. (KTTA) - 424B3 SEC Filings 11/30/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 11/29/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 11/28/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 11/28/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 11/22/2022
Pasithea Therapeutics Corp. (KTTA) - DEFC14A SEC Filings 11/17/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 11/17/2022
Pasithea Therapeutics Corp. (KTTA) - DEFC14A SEC Filings 11/15/2022
Pasithea Therapeutics Corp. (KTTA) - PRER14A SEC Filings 11/14/2022
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 11/01/2022
Pasithea Therapeutics Corp. (KTTA) - PREC14A SEC Filings 11/01/2022
Pasithea Therapeutics Corp. (KTTA) - PRE 14A SEC Filings 10/31/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 10/26/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 10/24/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 10/21/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13G SEC Filings 10/20/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 10/19/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 10/17/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 10/13/2022
Pasithea Therapeutics Corp. (KTTA) - PRRN14A SEC Filings 10/12/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 10/12/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 10/12/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 10/04/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 09/30/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 09/29/2022
Pasithea Therapeutics Corp. (KTTA) - PREC14A SEC Filings 09/23/2022
Pasithea Therapeutics Corp. (KTTA) - S-8 SEC Filings 09/21/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 09/20/2022
Pasithea Therapeutics Corp. (KTTA) - 424B3 SEC Filings 09/16/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 09/06/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 09/06/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 09/06/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 09/01/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 08/31/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K/A - Current report SEC Filings 08/29/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 08/26/2022
Pasithea Therapeutics Corp. (KTTA) - 3 SEC Filings 08/26/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 08/24/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 08/18/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 08/18/2022
Pasithea Therapeutics Corp. (KTTA) - 3 SEC Filings 08/16/2022
Pasithea Therapeutics Corp. (KTTA) - 3 SEC Filings 08/15/2022
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 08/15/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 08/11/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 08/11/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 08/05/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 08/02/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 07/28/2022
Pasithea Therapeutics Corp. (KTTA) - DEFC14A SEC Filings 07/28/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 07/27/2022
Pasithea Therapeutics Corp. (KTTA) - PREC14A SEC Filings 07/26/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 07/26/2022
Pasithea Therapeutics Corp. (KTTA) - PRE 14A SEC Filings 07/15/2022
Pasithea Therapeutics Corp. (KTTA) - DEFC14A SEC Filings 07/14/2022
Pasithea Therapeutics Corp. (KTTA) - PRRN14A SEC Filings 07/13/2022
Pasithea Therapeutics Corp. (KTTA) - PREC14A SEC Filings 07/01/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 06/30/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13G SEC Filings 06/29/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 06/27/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K/A - Current report SEC Filings 06/27/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 06/27/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 06/24/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K/A - Current report SEC Filings 06/24/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 06/24/2022
Pasithea Therapeutics Corp. (KTTA) - DFAN14A SEC Filings 06/23/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 06/23/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 06/23/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 06/22/2022
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 06/22/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D/A SEC Filings 06/16/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 06/10/2022
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 06/09/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13D SEC Filings 06/01/2022
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 05/16/2022
Pasithea Therapeutics Corp. (KTTA) - DEFA14A SEC Filings 05/13/2022
Pasithea Therapeutics Corp. (KTTA) - DEF 14A SEC Filings 05/13/2022
Pasithea Therapeutics Corp. (KTTA) - 10-K/A - Current report SEC Filings 05/12/2022
Pasithea Therapeutics Corp. (KTTA) - 424B3 SEC Filings 04/18/2022
Pasithea Therapeutics Corp. (KTTA) - 10-K - Current report SEC Filings 03/30/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13G/A SEC Filings 02/03/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13G/A SEC Filings 02/01/2022
Pasithea Therapeutics Corp. (KTTA) - SC 13G/A SEC Filings 01/13/2022
Pasithea Therapeutics Corp. (KTTA) - 424B3 SEC Filings 12/22/2021
Pasithea Therapeutics Corp. (KTTA) - 4 SEC Filings 12/22/2021
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 12/21/2021
Pasithea Therapeutics Corp. (KTTA) - 424B3 SEC Filings 12/21/2021
Pasithea Therapeutics Corp. (KTTA) - SC 13G SEC Filings 12/20/2021
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 12/17/2021
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 12/17/2021
Pasithea Therapeutics Corp. (KTTA) - UPLOAD SEC Filings 12/14/2021
Pasithea Therapeutics Corp. (KTTA) - CORRESP SEC Filings 12/14/2021
Pasithea Therapeutics Corp. (KTTA) - S-1 SEC Filings 12/09/2021
Pasithea Therapeutics Corp. (KTTA) - D SEC Filings 12/07/2021
Pasithea Therapeutics Corp. (KTTA) - 8-K - Current report SEC Filings 11/29/2021
Pasithea Therapeutics Corp. (KTTA) - 10-Q - Quarterly Report SEC Filings 11/18/2021
Pasithea Therapeutics Corp. (KTTA) - NT 10-Q - Quarterly Report SEC Filings 11/16/2021
Pasithea Therapeutics Corp. (KTTA) - SC 13G SEC Filings 11/04/2021
Pasithea Therapeutics Corp. (KTTA) - 3/A SEC Filings 10/07/2021
Pasithea Therapeutics Corp. (KTTA) - SC 13G SEC Filings 09/22/2021
Pasithea Therapeutics Corp. (KTTA) - 424B4 SEC Filings 09/16/2021
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 09/15/2021
Pasithea Therapeutics Corp. (KTTA) - EFFECT SEC Filings 09/15/2021
Pasithea Therapeutics Corp. (KTTA) - S-1MEF SEC Filings 09/14/2021
Pasithea Therapeutics Corp. (KTTA) - CERT SEC Filings 09/14/2021
Pasithea Therapeutics Corp. (KTTA) - 3 SEC Filings 09/14/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 09/13/2021
Pasithea Therapeutics Corp. (KTTA) - 8-A12B SEC Filings 09/13/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 09/10/2021
Pasithea Therapeutics Corp. (KTTA) - CORRESP SEC Filings 09/10/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 08/27/2021
Pasithea Therapeutics Corp. (KTTA) - FWP SEC Filings 08/27/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 08/26/2021
Pasithea Therapeutics Corp. (KTTA) - FWP SEC Filings 08/26/2021
Pasithea Therapeutics Corp. (KTTA) - CORRESP SEC Filings 08/26/2021
Pasithea Therapeutics Corp. (KTTA) - UPLOAD SEC Filings 08/11/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 08/06/2021
Pasithea Therapeutics Corp. (KTTA) - FWP SEC Filings 08/06/2021
Pasithea Therapeutics Corp. (KTTA) - CORRESP SEC Filings 08/05/2021
Pasithea Therapeutics Corp. (KTTA) - UPLOAD SEC Filings 07/01/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 06/22/2021
Pasithea Therapeutics Corp. (KTTA) - FWP SEC Filings 06/22/2021
Pasithea Therapeutics Corp. (KTTA) - CORRESP SEC Filings 06/21/2021
Pasithea Therapeutics Corp. (KTTA) - UPLOAD SEC Filings 06/16/2021
Pasithea Therapeutics Corp. (KTTA) - S-1/A SEC Filings 06/04/2021
Pasithea Therapeutics Corp. (KTTA) - CORRESP SEC Filings 06/04/2021
Pasithea Therapeutics Corp. (KTTA) - UPLOAD SEC Filings 05/10/2021
Pasithea Therapeutics Corp. (KTTA) - S-1 SEC Filings 04/13/2021
Pasithea Therapeutics Corp. (KTTA) - D SEC Filings 03/19/2021
Pasithea Therapeutics Corp. (KTTA) - D SEC Filings 01/29/2021

Press Releases

StockPrice Release
Pasithea therapeutics announces pas-004 abstract accepted for poster presentation at 2024 asco annual meeting 04/29/2024
Pasithea therapeutics announces the first cohort has completed the initial dosing in its phase 1 trial evaluating pas-004 in ras, nf1 and raf mutated cancers 04/24/2024
Pasithea therapeutics announces opening of enrollment in the u.s. for its phase 1 trial of pas-004 02/13/2024
Pasithea therapeutics announces invention of crystalline form of pas-004; establishes strengthened intellectual property (ip) position 01/08/2024
Pasithea therapeutics announces fda acceptance of ind application to evaluate pas-004 in advanced cancer patients 01/02/2024
Pasithea therapeutics announces adjournment of reconvened meeting of stockholders to december 29, 2023 12/28/2023
Pasithea therapeutics announces results from 2023 annual meeting 12/19/2023
Pasithea therapeutics announces positive in vivo preclinical efficacy data for pas-004 from nras mutation cancer xenograft models 12/11/2023
Pasithea therapeutics announces adjournment of 2023 annual meeting of stockholders 11/29/2023
Pasithea therapeutics announces outcome of pre-ind meeting with fda for pas-004 clinical development 11/29/2023
Pasithea therapeutics selects pas-003 lead development candidate, a humanized monoclonal antibody that targets Α5Β1 integrin for the treatment of both sporadic and familial als 11/09/2023
Pasithea therapeutics corp. announces final results of tender offer 09/14/2023
Pasithea therapeutics to participate in h.c. wainwright 25th annual global investment conference 09/07/2023
Pasithea therapeutics publishes study in proceedings of the national academy of sciences (pnas) that shows an increase in Α5 integrin expression in als human and mouse brain tissue, and further demonstrates targeting Α5 integrin results in improved survival and motor function 08/01/2023
Pasithea therapeutics announces intention to commence a $4.0 million tender offer for its common stock at price of $0.70 per share in cash 07/20/2023
Pasithea therapeutics special committee rejects unsolicited bid from lucy scientific discovery, inc. 07/20/2023
Pasithea therapeutics confirms previous creation of independent special committee of its board of directors 06/30/2023
Pasithea therapeutics confirms receipt of unsolicited proposal from lucy scientific discovery inc. 06/06/2023
Pasithea therapeutics chairman, prof. lawrence steinman to receive pioneer in medicine award 02/16/2023
Pasithea therapeutics signs cmc development and manufacturing agreement for the production of pas-004 01/18/2023
Majority of stockholders support pasithea directors at special meeting 12/14/2022
Pasithea therapeutics postpones special meeting until december 9, 2022 at 9:00 am eastern time 11/28/2022
Investor group comments on pasithea therapeutics' seemingly defensive and ill-timed acquisition of allomek therapeutics 10/13/2022
Pasithea therapeutics to call special meeting of stockholders 10/03/2022
Investor group successful in request to call special meeting of stockholders of pasithea therapeutics 09/06/2022
Investor group urges stockholders of pasithea therapeutics to vote to call special meeting 08/24/2022
Investor group urges stockholders of pasithea therapeutics corp. to call special meeting 08/05/2022
Pasithea therapeutics announces financial and business results for the fourth quarter and full year 2021 and business update for 2022 03/30/2022
Pasithea therapeutics corp. announces closing of $30.4 million private placement priced at a premium to the market under nasdaq rules 11/29/2021
Pasithea therapeutics corp. announces pricing of a $30.4 million private placement priced at a premium to the market under nasdaq rules 11/24/2021

More Headlines

News
Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%. 12/13/2023
Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? Pasithea Therapeutics (NASDAQ: KTTA ) stock is rocketing higher on Monday after the biotechnology company announced results from two preclinical trials of PAS-004. The first study saw positive results from PAS-004 as a treatment for lung cancer. 12/11/2023
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24. 12/11/2023
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA), today announced that its annual meeting of stockholders held on November 29, 2023 (the “Annual Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals described in the Company's definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on October 26, 2023 (the “Proxy Statement”). 11/29/2023
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development -- Company on track to submit PAS-004 IND application in current quarter -- -- Pasithea plans to begin PAS-004 Phase 1 dose escalation trial in advanced solid tumor patients harboring RAS, RAF and NF1 mutations -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, announced receipt of written responses to questions submitted for a Type 2 pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding clinical development plan for PAS-004. 11/29/2023
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS 11/09/2023
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer PALO ALTO, Calif. and MIAMI, Sept. 09/14/2023
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference -- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13. 09/07/2023
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function -- PAS-003 is a monoclonal antibody targeting α 5/ β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) -- -- Lead α 5/ β1 integrin drug candidate to be selected in H2 2023 -- 08/01/2023
Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash PALO ALTO, Calif. and MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced that its Board of Directors (the "Board") has authorized the repurchase, through a $4.0 million tender offer ("Tender Offer"), of up to approximately 5.7 million shares of the Company's outstanding common stock, at an anticipated cash purchase price of $0.70 per share. 07/20/2023
Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. Proposal Does Not Adequately Reflect Pasithea's Strategic Value and Prospects for Continued Growth Proposal Does Not Adequately Reflect Pasithea's Strategic Value and Prospects for Continued Growth 07/20/2023
Hot Penny Stocks For Your January 2022 Watchlist Making a penny stocks watchlist for January? Check these three out The post Hot Penny Stocks For Your January 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 12/29/2021
Top Penny Stocks to Watch During Today's Bull Run Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 12/23/2021
KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today Pasithea Therapeutics (KTTA) stock is heading higher on heavy trading Thursday even without any recent news from the biotech company. The post KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today appeared first on InvestorPlace. 12/23/2021
Pasithea Therapeutics (KTTA) Stock: Why The Price Jumped Today The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 25% pre-market today. This is why it happened. 11/24/2021
Hot Penny Stocks Today: Why Is KTTA Stock Moving? Shares of penny stock KTTA are on the move and here's what's going on. The post Hot Penny Stocks Today: Why Is KTTA Stock Moving? 11/23/2021
Pasithea Therapeutics (KTTA) Stock: Why The Price Surged Today The stock price of Pasithea Therapeutics Corp (NASDAQ: KTTA) increased by over 135% pre-market today. This is why it happened. 11/23/2021
Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders Ketamine in sub-anesthetic doses has shown to be highly effective at treating some psychiatric disorders, such as treatment resistant depression and post-traumatic stress disorder 10/14/2021
Pasithea Therapeutics: Revenues Just Around the Corner Pasithea Therapeutics ( KTTA , Financial) ( KTTAW , Financial) caught my eye recently as an emerging biotech player with a different approach to business. On first impression, the company may seem like any other listed development-stage biotechnology player which could take years to generate any kind of revenues and which will go through a string of public issues to finance its research, resulting in constant dilution. 10/12/2021
Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery Photo by CDC on Unsplash Pasithea Therapeutics ( NASDAQ: KTTA), a Florida-based biotechnology company, has teamed with life sciences company Evotec SE (OTCMKTS: EVTCY) as its research partner to help discover new compounds aimed at treating depression and schizophrenia. 10/11/2021
Pasithea, Evotec Ink Drug Development Pact Pasithea Therapeutics Corp (NASDAQ: KTTA) has initiated a new chemical entity development program and named Evotec SE (OTC: EVOTF) its research partner. No deal terms were disclosed. 10/11/2021

Unlock

KTTA Ratings Summary

KTTA Quant Ranking